| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $1,005,743 | 1 | 6 |
Sells | $1,959,768 | 16 | 94 |
| HAYES GREGORY | director | 1 | $1.01M | 0 | $0 | $1.01M |
| SCOTT BERTRAM L | director | 0 | $0 | 1 | $38,318 | $-38,318 |
| Feld Michael | EVP & President, Life Sciences | 0 | $0 | 6 | $76,604 | $-76,604 |
| Shan David | EVP and Chief ISC Officer | 0 | $0 | 1 | $199,608 | $-199,608 |
| Fraser Claire | director | 0 | $0 | 2 | $337,892 | $-337,892 |
| Byrd Richard | EVP & President Interventional | 0 | $0 | 2 | $541,895 | $-541,895 |
| Garrison Michael David | EVP & President, Medical | 0 | $0 | 4 | $765,450 | $-765,450 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Over the last 12 months, insiders at Becton, Dickinson and Company have bought $1.01M and sold $1.96M worth of Becton, Dickinson and Company stock.
On average, over the past 5 years, insiders at Becton, Dickinson and Company have bought $678,086 and sold $4.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: HAYES GREGORY (director) — $1.01M.
The last purchase of 5,250 shares for transaction amount of $1.01M was made by HAYES GREGORY (director) on 2025‑08‑11.
| 2026-01-26 | Sale | Feld Michael | EVP, CRO & Pres. Life Sciences | 75 <0.0001% | $202.73 | $15,205 | -0.67% | |
| 2026-01-15 | Sale | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 1,610 0.0006% | $207.46 | $334,005 | -2.00% | |
| 2025-12-26 | Sale | Feld Michael | EVP, CRO & Pres. Life Sciences | 74 <0.0001% | $196.08 | $14,510 | +3.35% | |
| 2025-12-17 | Sale | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 629 0.0002% | $196.03 | $123,303 | +3.41% | |
| 2025-12-01 | Sale | Feld Michael | EVP, CRO & Pres. Life Sciences | 75 <0.0001% | $193.36 | $14,502 | +4.71% | |
| 2025-11-07 | Sale | SCOTT BERTRAM L | director | 217 <0.0001% | $176.58 | $38,318 | +10.62% | |
| 2025-10-27 | Sale | Feld Michael | EVP & President, Life Sciences | 57 <0.0001% | $186.01 | $10,603 | +4.85% | |
| 2025-09-26 | Sale | Feld Michael | EVP & President, Life Sciences | 58 <0.0001% | $181.03 | $10,500 | +4.86% | |
| 2025-09-10 | Sale | Fraser Claire | director | 917 0.0003% | $187.50 | $171,938 | +1.96% | |
| 2025-08-22 | Sale | Feld Michael | EVP & President, Life Sciences | 57 <0.0001% | $197.99 | $11,285 | -3.40% | |
| 2025-08-11 | HAYES GREGORY | director | 5,250 0.0018% | $191.57 | $1.01M | +0.51% | ||
| 2025-08-08 | Sale | Fraser Claire | director | 863 0.0003% | $192.30 | $165,955 | -0.06% | |
| 2025-07-18 | Sale | Garrison Michael David | EVP & President, Medical | 1,185 0.0004% | $180.29 | $213,645 | +7.66% | |
| 2025-06-02 | Sale | Shan David | EVP and Chief ISC Officer | 1,166 0.0004% | $171.19 | $199,608 | +12.91% | |
| 2025-04-09 | Sale | Garrison Michael David | EVP & President, Medical | 479 0.0002% | $197.28 | $94,497 | -8.92% | |
| 2025-03-18 | Sale | Byrd Richard | EVP & President Interventional | 459 0.0002% | $230.00 | $105,570 | -17.11% | |
| 2025-03-12 | Sale | Byrd Richard | EVP & President Interventional | 1,940 0.0007% | $224.91 | $436,325 | -13.92% | |
| 2025-02-12 | Sale | SCOTT BERTRAM L | director | 700 0.0002% | $227.99 | $159,593 | -13.81% | |
| 2025-02-10 | Henderson Jeffrey William | director | 1,500 0.0005% | $233.62 | $350,430 | -15.09% | ||
| 2025-01-21 | Sale | Neal Shana Carol | EVP and Chief People Officer | 787 0.0003% | $240.00 | $188,880 | -18.87% |
| SCOTT BERTRAM L | director | 35816 0.0099% | $6.36M | 0 | 4 | |
| Fraser Claire | director | 22226 0.0061% | $3.94M | 0 | 9 | |
| Feld Michael | EVP, CRO & Pres. Life Sciences | 16431 0.0045% | $2.92M | 0 | 6 | |
| Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | 12095 0.0033% | $2.15M | 0 | 9 | |
| Byrd Richard | EVP & President Interventional | 6952 0.0019% | $1.23M | 0 | 5 | |
| HAYES GREGORY | director | 6046 0.0017% | $1.07M | 1 | 0 | |
| Shan David | EVP and Chief ISC Officer | 4575 0.0013% | $811,788.00 | 0 | 3 | |
| FORLENZA VINCENT A | Chairman of the Board | 208864 0.0577% | $37.06M | 0 | 26 | |
| LUDWIG EDWARD J | Chairman | 97188 0.0268% | $17.25M | 0 | 39 | |
| RING TIMOTHY M | director | 93688 0.0259% | $16.62M | 0 | 3 | |
| CONSIDINE JOHN R | Vice Chairman | 89650 0.0247% | $15.91M | 0 | 7 | |
| COHEN GARY M | Executive Vice President | 71770 0.0198% | $12.73M | 0 | 21 | |
| KOZY WILLIAM A | Executive Vice President | 68823 0.019% | $12.21M | 0 | 23 | |
| HANSON ALFRED JOHN | Executive Vice President | 40273 0.0111% | $7.15M | 0 | 5 | |
| Polen Thomas E Jr | Chairman, CEO and President | 28878 0.008% | $5.12M | 0 | 10 | |
| BECTON HENRY P JR | director | 23820 0.0066% | $4.23M | 0 | 56 | |
| ORR JAMES F | director | 23045 0.0064% | $4.09M | 0 | 3 | |
| SHERMAN JEFFREY S | Sr. VP and General Counsel | 22094 0.0061% | $3.92M | 0 | 17 | |
| Conroy Alexandre | EVP of Integrated Supply Chain | 21260 0.0059% | $3.77M | 0 | 8 | |
| OVERLOCK WILARD J JR | director | 21091 0.0058% | $3.74M | 2 | 2 | +1.25% |
| Mecklenburg Gary A | director | 20965 0.0058% | $3.72M | 0 | 1 | |
| Lim James C | Executive Vice President | 19768 0.0055% | $3.51M | 0 | 10 | |
| DEGRAAN EDWARD | director | 18608 0.0051% | $3.3M | 0 | 1 | |
| ANDERSON BASIL | director | 17221 0.0048% | $3.06M | 0 | 1 | |
| SOMMER ALFRED | director | 16228 0.0045% | $2.88M | 0 | 5 | |
| Neal Shana Carol | EVP and Chief People Officer | 15414 0.0043% | $2.74M | 0 | 3 | |
| Boles Donna M | Senior VP - Human Resources | 14607 0.004% | $2.59M | 0 | 8 | |
| Goette Roland | EVP and President, EMEA | 14217 0.0039% | $2.52M | 0 | 6 | |
| TOZZI WILLIAM A | EVP Pres Interventional | 13208 0.0036% | $2.34M | 0 | 13 | |
| Tharby Linda M | Executive Vice President | 11337 0.0031% | $2.01M | 0 | 4 | |
| Campion Simon D | EVP and Segment President | 10773 0.003% | $1.91M | 0 | 2 | |
| RIMEL REBECCA W | director | 10618 0.0029% | $1.88M | 0 | 6 | |
| Kaltenbach Patrick | EVP & Pres Life Sciences | 10340 0.0029% | $1.83M | 0 | 9 | |
| UGGLAS MARGERETHA AF | director | 10000 0.0028% | $1.77M | 1 | 0 | +22.59% |
| BURZIK CATHERINE M | director | 10007 0.0028% | $1.78M | 3 | 1 | +5.53% |
| BEATY HARRY N | director | 9204 0.0025% | $1.63M | 0 | 1 | |
| DURACK DAVID T | Senior Vice President | 8382 0.0023% | $1.49M | 0 | 22 | |
| Mas Ribo Alberto | EVP and Pres, Life Sciences | 8381 0.0023% | $1.49M | 0 | 6 | |
| Henderson Jeffrey William | director | 8015 0.0022% | $1.42M | 1 | 0 | |
| SHRADER PATRICIA B | Senior Vice President | 7915 0.0022% | $1.4M | 0 | 4 | |
| Sichak Stephen | Executive Vice President | 7953 0.0022% | $1.41M | 0 | 11 | |
| Shabshab Nabil | Executive Vice President | 7811 0.0022% | $1.39M | 0 | 5 | |
| Bruder Scott P | SrVP; Chief Technology Officer | 7626 0.0021% | $1.35M | 0 | 1 | |
| Strahlman Ellen R | Senior Vice President | 6037 0.0017% | $1.07M | 0 | 2 | |
| Khichi Samrat S. | EVP and General Counsel | 5928 0.0016% | $1.05M | 0 | 3 | |
| Larson Betty D | EVP HR & CHRO | 5872 0.0016% | $1.04M | 0 | 3 | |
| Elkins David V | Executive VP and CFO | 5513 0.0015% | $978,226.72 | 0 | 1 | |
| DAGEVILLE JEAN MARC | VP - Human Resources | 4658 0.0013% | $826,515.52 | 0 | 1 | |
| Hickey David | EVP & President, Life Sciences | 4199 0.0012% | $745,070.56 | 0 | 4 | |
| Minehan Cathy E. | director | 3000 0.0008% | $532,320.00 | 2 | 0 | +2.04% |
| Melcher David F | director | 2728 0.0008% | $484,056.32 | 1 | 0 | +8.75% |
| Borzi James W | EVP & Chief Supply Chain Offcr | 2775 0.0008% | $492,396.00 | 0 | 2 | |
| Hurwitz Jerome V | Executive Vice President | 3027 0.0008% | $537,110.88 | 0 | 4 | |
| Gallagher John E | VP, Corp Finance and Treasurer | 2099 0.0006% | $372,446.56 | 0 | 5 | |
| Bodner Charles R | SVP Corp Fin Chief Acct Office | 2037 0.0006% | $361,445.28 | 0 | 2 | |
| Spoerel Thomas J | SVP,Controller&Chief Acct Off | 1976 0.0005% | $350,621.44 | 0 | 7 |
| Increased Positions | 665 | +35.93% | 27M | +10.05% |
| Decreased Positions | 821 | -44.35% | 27M | -10.09% |
| New Positions | 180 | New | 3M | New |
| Sold Out Positions | 145 | Sold Out | 6M | Sold Out |
| Total Postitions | 1,695 | -8.43% | 267M | -0.04% |
| Vanguard Group Inc | $6.33M | 11.39% | 32.46M | +147,041 | +0.46% | 2025-09-30 |
| Blackrock, Inc. | $5.41M | 9.74% | 27.75M | +472,432 | +1.73% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $3.16M | 5.7% | 16.23M | +54,113 | +0.33% | 2025-09-30 |
| State Street Corp | $2.7M | 4.87% | 13.87M | +459,219 | +3.42% | 2025-09-30 |
| First Eagle Investment Management, Llc | $1.95M | 3.51% | 9.99M | +1M | +13.75% | 2025-09-30 |
| Massachusetts Financial Services Co /Ma/ | $1.78M | 3.21% | 9.15M | +636,138 | +7.47% | 2025-09-30 |
| Geode Capital Management, Llc | $1.33M | 2.4% | 6.83M | +107,775 | +1.6% | 2025-09-30 |
| Franklin Resources Inc | $1.31M | 2.36% | 6.74M | +4M | +150.85% | 2025-09-30 |
| Jpmorgan Chase & Co | $1.03M | 1.86% | 5.29M | +743,678 | +16.37% | 2025-09-30 |
| Wellington Management Group Llp | $1.02M | 1.84% | 5.23M | +5M | +9,056.29% | 2025-09-30 |